Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Received my Virtual Special Meeting info in yesterday's mail. For those of us who got screwed by Ks and Cs, how should we vote our shares?
https://www.worldatlas.com/articles/the-world-s-largest-producers-of-niobium.html
Hey there web...buzz me if you still have my number!
Still holding a chunk myself.
Best!
What's the upside here? Thx!
Yup....totally agree!
and .66 ain't too shabby either!
Always viewed this company as a baseball analogy: "Leo at the Bat"
...three strikes and we're all out...but so far we haven't even swung the bat once yet. We get 3 strikes, 1 for each B,P,K. We're still in the "on deck" circle imo.
This panic looks as if some of our fans think the game has been called...that we won't even get up to the plate.
Well, I think we will. And I also believe that there will be upward price movement when
the batter walks from the on deck circle to the plate.
We shall see! JMHO
Screaming buy...thank you! Panickers have given us a treat...I hope...and believe. Long wait till June dog and pony show.
I expect news next week.
Things moving along very nicely.... Thinking 80 cents to a buck over the next year...on Romania only. Just wait for Pel 444 to kick in...that's the elephant!
Possible triple bottom coming into play at 94-95 cents...but i added here at 1.11 yesterday anyway. Near term upside target $1.50. Just my guess.
Isn't TGC considered to be the "operator?" If so, don't they control the drilling timeline? And isn't HENC required to put up the vast majority of the cash for at least the next well?
Got go back and do some re-reading!
Yes...like it like it. Thank you Perseville, thank you Carlo. Hey Henc-ers whats your take on this?
imo, again, it doesn't really matter when it was done... sub penny or a nickle or more... 30% is nothing given the upside here. And if the dilution were done sub penny, that would be the worst, most dilutive way to have raised funds or paid for any expenses with shares, right?
imo, a 30% dilution for a sub/penny is nothing. Glass is half full...and getting fuller.
Who controls the drilling on the 2 PELs? Isn't TGC still considered the "operator."
Yes, it loooks like TGC will be moving along with this new venture, lower risk developmental drilling... as I've been told. Wonder if Henc has any plans now?
And Henc also lacks money & desire apparently.
Don't know about short sales, but I like new talent with a pedigree of success
This ancient volcano owned by this company has the potential of 35 cents per share over the next 2 years imo. There's some extremely interesting steps being taken that will soon light the fuse and bring lots of interest to this loooong drawn out situation....finally!.
Very pleased with what I've heard and believe to be THE TRUTH.
Long term holder more excited and anxious about this company than I've been in years.
Of course...do your own DD and Caveat Emptor!
Oh no, not another Patrick Cox endorsement...often the kiss of death...or at least the kiss of LOOOOOOONNG WAIT! Broken clock is right twice per day...I hope Patrick is broken!
Wonder if a secondary is in the works?
These Purisol results de-risk this play just like B did. If we get good results on B and K, shareholder risk will be approaching 0!
Just kidding...like the price action here, like the P results...they actually do lessen shareholder risk imho!
Celgene to Buy Receptos for $7.2 Billion
Deal-making spree continues for Celgene, adding to its portfolio of autoimmune-disease treatments
Updated July 14, 2015 7:05 p.m. ET
Cancer-drug company Celgene Corp. on Tuesday said it will pay $7.2 billion for Receptos Inc. in a bid to move deeper into the multibillion-dollar market for autoimmune diseases.
Under the terms, Celgene will pay $232 a share for Receptos, a 12% premium to Tuesday’s closing price. Receptos stock, which traded at $107.22 a share in late January, had risen in recent months amid takeover speculation.
Celgene, which expects the deal to close in the third quarter, has been trying to diversify beyond its foothold in drugs treating multiple myeloma. About 65% of its $7.6 billion in 2014 total product sales came from just one of these drugs, Revlimid. But such blood-cancer drugs are aging and rivals are challenging patents.
Drugs for autoimmune diseases like rheumatoid arthritis, ulcerative colitis and psoriasis, offer one of the pharmaceutical industry’s biggest markets. Summit, N.J.-based Celgene pegs the market at $67 billion in sales last year and the potential to reach $93 billion in 2020. Humira, the world’s top-selling drug, treats autoimmune diseases.
Last year, the Food and Drug Administration approved a Celgene drug called Otezla for psoriasis, and the company is developing another therapy for Crohn’s disease.
Receptos would give Celgene a third autoimmune drug, treating ulcerative colitis and multiple sclerosis, to round out a lineup of autoimmune treatments to offer to doctors and patients. The San Diego biotech has been in the later stages of developing the drug, dubbed Ozanimod. Celgene estimates the drug could have $4 billion to $6 billion in yearly sales if it wins approval.
“We’re creating a complementary portfolio,” Celgene CEO Robert Hugin said in a conference call with analysts reviewing the deal. He said Ozanimod will help Celgene “really build a major franchise.”
The transaction is the latest in a hot deals market in the drug industry. Celgene has been among the big deal makers, agreeing last month to pay $1 billion upfront to Juno Therapeutics Inc. to acquire a 10% stake and collaborate on the development of cancer immunotherapies.
Mr. Hugin said Celgene expects the Receptos deal to add to earnings starting in 2019.
Celgene CFO Peter Kellogg said the company would use its own cash as well as offer about $5 billion in bonds in August to finance the transaction. Receptos has $600 million in cash, Celgene said.
As a result of the Receptos agreement, Celgene is raising its financial targets for 2020, projecting net product sales of more than $21 billion.
Celgene reports earnings later this month, but said it expects second-quarter earnings of $2.3 billion, up 22% over the period a year earlier, and adjusted earnings per share to increase 37% to $1.23, including a six-cent gain on the sale of an equity investment.
—Josh Beckerman contributed to this article
From the 10Q:
Overview
We are a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics for immune disorders. Our product candidates span three distinct specialty disease areas. We are developing our lead asset, ozanimod, as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn’s Disease (CD). We are developing our second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), which is an Orphan Disease. Our strategy is to develop best-in-class drug candidates and selectively pursue first-in-class market positions. The mechanism of actions for each of our product candidates has been validated in one or more immunology indications.
Since our inception, we have focused our attention on, and devoted substantial resources to, developing ozanimod and RPC4046. We are focused on three indications for ozanimod, which are being studied in advanced stage clinical trials. We have initiated a randomized Phase 2 study of RPC4046. In addition, we have a research program developing oral, small molecule positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-IR) for the treatment of Type 2 Diabetes.
We have entered into various collaboration arrangements and a license arrangement related to our G protein-coupled receptor (GPCR) structure-based drug design technology platform, all of which, except for one, have been completed or terminated. Under these agreements we received upfront payments, license fees, research and development funding and research and/or development milestones. We have not generated any revenue from product sales. Through June 30, 2015, we have funded our operations primarily through the sale of our stock and through the receipt of upfront payments, research funding and preclinical milestones from our collaboration arrangements.
We have incurred significant operating losses since our inception in 2008 and, as of June 30, 2015, we had an accumulated deficit of $316.8 million. Substantially all of our operating losses resulted from expenses incurred in connection with our drug candidate development programs, our research activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. In the near term, we anticipate that our expenses will increase substantially as we:
·
advance the current Phase 3 studies of ozanimod in RMS and UC;
·
prepare for and initiate a Phase 2 study of ozanimod in CD;
·
advance the current Phase 2 study of RPC4046 in EoE;
·
continue research efforts;
·
maintain, expand and protect our intellectual property portfolio; and
·
hire additional staff, including clinical, scientific, operational, finance and management personnel.
To fund future operations we will likely need to raise additional capital. Our existing cash, cash equivalents and short-term investments will not be sufficient for us to commercialize any product candidate which may receive approval. Accordingly, we will continue to require substantial additional capital for our clinical development and potential commercialization activities. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. We anticipate that we will seek to fund our operations through public or private equity or debt financings or other sources, such as potential collaboration arrangements. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategies.
On July 14, 2015, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Celgene Corporation, a Delaware corporation (“Celgene”), and Strix Corporation, a Delaware corporation and a wholly owned subsidiary of Celgene (“Purchaser”), pursuant to which, and on the terms and subject to the conditions thereof, among other things, on July 28, 2015 Purchaser commenced a tender offer (“Offer”) to acquire all of our outstanding shares of common stock (the “Company Shares”), subject to certain customary exceptions set forth in the Merger Agreement, at a purchase price of $232.00 per Company Share net to
1
Buy those solid companies while they are down.
Hey Citrati....wheres the next support levels here?
This will need some news to get moving again...but I am picking here!
Are we toast here...or even something less...burnt crumbs?
O/S is 137 million shares I believe not 13 million
GRIFFIN SECURITIES
Member FINRA, SIPC
Keith A. Markey, Ph.D., M.B.A.
kmarkey@griffinsecurities.com
212-514-7914
Stock Symbol NYSE:MKT: SYN
Current Price $2.45
12 mos. Target Price $9.00
Market Cap $222.5 mln
Synthetic Biologics BUY
Company Update : Biotechnology
Clinical Data Looks Promising
Please click here for full report, including disclosures
Synthetic’s Microbiome Clinical Program provided updates on its two lead drugs, a prophylactic for Clostridium difficile infections and a therapy for irritable bowel syndrome with constipation (IBS-C).
SYN-004 has a protective effect on the microbiome of the gastrointestinal tract as evidenced by its ability to degrade a commonly used IV antibiotic, ceftriaxone. The results from eight of ten individuals were very consistent in showing that two dosage strengths of SYN-004 reduced the antibiotic to undetectable levels without altering its plasma levels. Moreover, Synthetic’s drug was not detectable in the plasma and caused no serious adverse events. Two individuals were “outliers,” which may be due to the conditions that necessitated their ileostomies. We believe the data indicate that SYN-004 protects the gut microbiome against IV beta-lactam antibiotics that reach the GI tract. Another Phase 2a trial testing SYN-004 in the presence of a proton pump inhibitor will report data early next year and a large Phase 2b trial is enrolling hospitalized patients treated with ceftriaxone for pneumonia.
A Phase 2 trial showed a favorable trend in the effect of SYN-010 on IBS-C. The study tested two dosage strengths (21 or 42 mg/day) against a placebo over 28 days in 63 subjects with high methane levels in their breath (>10 ppm) at screening. Both doses of significantly reduced breath methane levels by day 28 and the IBS Global Assessment of Improvement showed a time- and dose-dependent benefit with the 42 mg dose. An 8-week extension study is assessing the 42 mg dose in the 54 patients who volunteered for this additional portion of the trial. The results should be available in the March quarter of 2016.
Synthetic Biologics is on track with its lead projects. SYN-010 will likely enter a Phase 3 trial in mid-2016 with results coming in the 2017 first quarter. The Phase 2b trial of SYN-004 may set the stage for a Phase 3 study during the 2016/17 flu season.
Both drugs have impressive sales potential. Only palliative treatments, for IBS-C are available today, so SYN-010 may be the first therapy in a large lucrative market. Similarly, SYN-004 should support the U.S. government’s efforts to reduce antibiotic resistance by enabling beta-lactams to be used as needed without the threat of follow-on C. difficile infections and antibiotic-associated diarrhea.
We are maintaining our BUY rating and $9 price target.
Answer: one of the miscreants?
Wildcat chance of success is 45% in the Cooper and Ero basins using 3D seismic. Where does this 10% come from?
With just 2D seismic, the odds of success are 33%. 10%...? Splain?
self-deleted
Slide 13 of the presentation...we have 4x the number of oil 1480 vs. 316 hectares that Senex has.
http://www.terranovaenergyltd.com/i/pdf/presentations/presentation.pdf
PEL 111 just south of 444 where Senex has had so much success, is not without its failures...refer to section 3.1 in the various PEL 111 annual reports:
http://petroleum.statedevelopment.sa.gov.au/old-site/legislation/company_annual_reports/cooper_and_eromanga_basins_annual_reports/pel_111
We've got the cash available to drill more...wonder if HENC will participate or fold their oil exploration hopes? TGC management made a smart move to cancel the original farm in/out agreement and focus on a multi well program where they pay for only their 20% WI and not the entire well...let's give credit where credit is due.
I don't know when we will drill again, but I'm certain will be it next year or even later. I plan to hold on to what I currently own and just wait it out...no fire sale for me...either way, buying or selling.
http://www.terranovaenergyltd.com/s/presentations.asp?ReportID=706048
Page 9 of the corporate presentation…. Jan 2002 thru December 2013 there were 215 exploration wells drilled in the Cooper basin, commercial success rate 40%, technical success rate 46%..
We just need to drill more wells, The odds favored a dry hole…shows the wisdom of wanting a multiwell program. Let’s hope we get one.
Dry holes happen...we're not alone:
http://www.aogdigital.com/energy/shale/item/4546-two-dry-wells-for-senex
yes...there is still hope for TGC shareholders. Nico has mentioned that there are other projects that TGC might consider in the event the 2 PELs were a bust. Looks like maybe they are. This well I assume was a total failure...not just a commercial or technical failure...but a complete failure.
Looks like we've opened up a new paradigm...$1 dollar invested becomes less than a "pair of dimes!" With the mess going on in the oil market, who know IF or when TGC will make another move...going to be awhile before anything is done would be my guess.
Sympathy...make that empathy...to all longs.